Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Reports: The Very Foundations of Medical Research.

A&A practice·2024
Same author

Characteristics and Outcomes of Patients in the Emergency Department with Left Ventricular Assist Devices.

The western journal of emergency medicine·2024
Same author

An Unusual Indication for Precordial Thump: Acute Prosthetic Valve Obstruction.

Journal of cardiothoracic and vascular anesthesia·2023
Same author

Transesophageal Echocardiography in Patients With Magnetic Gastroesophageal Reflux Devices: A Report of 2 Cases.

A&A practice·2021
Same author

Pulmonary artery sheath hematoma.

Annals of cardiac anaesthesia·2021
Same author

Cardiac Anesthesia Practices: The Known Unknowns.

Anesthesia and analgesia·2020

Related Experiment Video

Updated: Mar 25, 2026

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
09:54

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats

Published on: March 23, 2018

8.4K

Cardiopulmonary Bypass Without Heparin.

Kent H Rehfeldt1, David W Barbara2

  • 1Mayo Clinic, Rochester, MN, USA rehfeldt.kent@mayo.edu.

Seminars in Cardiothoracic and Vascular Anesthesia
|February 14, 2016
PubMed
Summary

Heparin is preferred for cardiopulmonary bypass (CPB), but alternatives are needed for patients with heparin-induced thrombocytopenia (HIT). Direct thrombin inhibitors, like bivalirudin, are recommended as safe and effective CPB anticoagulants in these cases.

Keywords:
HITPoint of Care Monitoringanticoagulantsbivalirudincardiopulmonary bypassheparinthrombin

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K
Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
08:08

Cardiopulmonary Bypass in a Mouse Model: A Novel Approach

Published on: September 22, 2017

11.7K

Related Experiment Videos

Last Updated: Mar 25, 2026

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
09:54

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats

Published on: March 23, 2018

8.4K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K
Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
08:08

Cardiopulmonary Bypass in a Mouse Model: A Novel Approach

Published on: September 22, 2017

11.7K

Area of Science:

  • Cardiovascular Surgery
  • Hematology
  • Pharmacology

Background:

  • Heparin is the standard anticoagulant for cardiopulmonary bypass (CPB) due to its favorable characteristics.
  • Heparin-induced thrombocytopenia (HIT) presents a challenge, necessitating alternative anticoagulation strategies for CPB.
  • Alternative anticoagulants are crucial when heparin is contraindicated, especially in urgent situations.

Purpose of the Study:

  • To review the use of heparin alternatives in patients undergoing CPB.
  • To focus on direct thrombin inhibitors as a primary alternative anticoagulant for CPB.
  • To provide guidance on managing anticoagulation in HIT patients requiring CPB.

Main Methods:

  • Literature review of studies on anticoagulation during CPB.
  • Analysis of clinical recommendations for managing HIT during cardiac operations.
  • Focus on direct thrombin inhibitors, specifically bivalirudin, as a heparin alternative.

Main Results:

  • Direct thrombin inhibitors are recommended as effective alternatives to heparin for CPB.
  • Bivalirudin is a key direct thrombin inhibitor explored for CPB in HIT patients.
  • The review highlights the feasibility of using non-heparin anticoagulants in specific clinical scenarios.

Conclusions:

  • Direct thrombin inhibitors offer a viable anticoagulation strategy for CPB when heparin is contraindicated.
  • Bivalirudin is a prominent option for anticoagulation during CPB in patients with HIT.
  • Careful selection of anticoagulants is essential for safe and effective CPB in patients with contraindications to heparin.